GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

GenSight Biologics Announces its 2022 Financial Calendar

GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe

GenSight Biologics reports clinically meaningful vision improvement is maintained 4 years after one-time treatment with LUMEVOQ® gene therapy

GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US